Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Investor Presentation (November 2013)

37 slides from Sorrento Therapeutics's investor presentation, Nov 19, 2013

  1. Slide 1: Next-Generation Cancer Therapeutics

    Slide 1: Next-Generation Cancer Therapeutics

    Exhibit 99.1 Sorrento Therapeutics Next-Generation Cancer Therapeutics November 2013

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement NASDAQ: SRNE This presentation contains "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), including statements regarding expectations, beliefs or intentions regarding our business, technologies and products

  3. Slide 3: Management Team

    Slide 3: Management Team

    Management Team Henry Ji, Ph.D. • Inventor of G-MAB ® Technology President & CEO, Director • President & CEO of Stratagene Genomics • VP of CombiMatrix and Stratagene Vuong Trieu, Ph.D. • Founder and CEO of IgDraSol CSO and Director • Co-inventor of IP covering Abraxane® • Instrumental in the approv

  4. Slide 4: Investment Highlights

    Slide 4: Investment Highlights

    Investment Highlights Late Stage Oncology Drug with Exclusive US and EU Rights • Addresses multi-billion dollar paclitaxel market • Abbreviated regulatory pathway (“bioequivalence”) for approval Cynviloq™ • Bioequivalence registration trial in 2014 (study direct costs ~ $5M) • Product launch in 1H 2

  5. Slide 5: Sorrento's Next-Generation Cancer Therapeutics

    Slide 5: Sorrento's Next-Generation Cancer Therapeutics

    Sorrento’s Next-Generation Cancer Therapeutics G-MAB® • High-diversity human Ab library • Lead mAb programs include PD-L1, PD-1, and CCR2 Cynviloq™ TUMOR • FTO and no stacking royalties Next-generation Abraxane® • Bioequivalence (BE) pathway for approval • Efficacy demonstrated • US and EU rights AD

  6. Slide 6: Pipeline

    Slide 6: Pipeline

    Pipeline INDICATION Metastatic Breast Cancer Non-Small Cell Lung Cancer } 505(b)(2) Bioequivalence 1H 2014 1H 2015 Cynviloq™ Pancreatic Cancer (BE* or sNDA) Bladder Cancer (sNDA) Multiple Ovarian Cancer (sNDA) PHASE 1 PHASE 2 RTX Refractory Pain in Cancer Patients In progress 1H 2015 Strategic INDIC

  7. Slide 7: Lead Product Opportunity Cynviloq

    Slide 7: Lead Product Opportunity Cynviloq

    Lead Product Opportunity Registration Cynviloq™ Trial 7

  8. Slide 8: Cynviloq is the 3rd Generation Paclitaxel Therapy

    Slide 8: Cynviloq is the 3rd Generation Paclitaxel Therapy

    rd Cynviloq is the 3 Generation Paclitaxel Therapy Maximum Peak Generation Formulation Tolerated Dose Product Sales st 1 Cremophor EL Taxol ® excipient: 175 mg/m 2 ~ $1.6B (WW in 2000) paclitaxel Polyoxyethylated castor oil nd Biological polymer: 2 260 mg/m 2 Est. >$1.7B* (US) Abraxane® Mean size Do

  9. Slide 9: Cynviloq is a High Value Proposition

    Slide 9: Cynviloq is a High Value Proposition

    Cynviloq is a High Value Proposition 1. Exclusive US and EU Rights 2. Cynviloq efficacy demonstrated in Phase 2 and Phase 3 studies a. Approved and marketed under brand name Genexol-PM in S. Korea 3. FDA concurred a. Available data support pursuing 505(b)(2) regulatory pathway b. Bioequivalence (BE)

  10. Slide 10: Clinical Efficacy & Safety Summary

    Slide 10: Clinical Efficacy & Safety Summary

    Clinical Efficacy & Safety Summary Total number of patients across all trials: 1,260 Phase 1: Trials established higher MTD in US - Dana Farber Cancer Inst, Russia, & S. Korea (total n=80) 2 2 2 >300 mg/m (q3w) vs. 175 mg/m (Taxol; weekly) and 275 mg/m (Abraxane; q3w) Phase 2: Completed trials in MB

  11. Slide 11: Equivalent Pharmacokinetics in Mice

    Slide 11: Equivalent Pharmacokinetics in Mice

    Equivalent Pharmacokinetics in Mice Abraxane Cynviloq AUCinf Drug HL (h) T max (h) Vz (mL/kg) Cl (mL/h/kg) (h*ng/mL) Abraxane 2.99 0.08 61561.33 2103.71 487.32 Cynviloq 2.83 0.08 58151.31 2103.58 515.90 IV bolus at 30 mg/kg; n = 3 Data on file 11

  12. Slide 12: Comparable Pharmacokinetics in Human

    Slide 12: Comparable Pharmacokinetics in Human

    Comparable Pharmacokinetics in Human Data from 2 separate studies 2 (3 h infusion, 135 mg/m dose, n=3) Abraxane data from: Nurad K. Ibrahim, Phase I and Pharmacokinetic Study of ABI-007, a Cremophor-free, Protein-stabilized, Nanoparticle Formulation of Paclitaxel. Clinical Cancer Research 2002;8:103

  13. Slide 13: Simulated PK Parameters Supportive of BE

    Slide 13: Simulated PK Parameters Supportive of BE

    Simulated PK Parameters Supportive of BE: Cynviloq vs. Abraxane Comparison of mean non-compartmental pharmacokinetic parameters of 2 Cynviloq (T) and Abraxane (260 mg/m ) at 30 min infusion time: Cmax Ratio AUCinf Ratio (ng/mL) Cmax(T)/Cmax(R) (ng*h/mL) AUCinf(T)/AUCinf(R) Cynviloq 19486 22198 (Simu

  14. Slide 14: Bioequivalence = Efficient Pathway to Market

    Slide 14: Bioequivalence = Efficient Pathway to Market

    Bioequivalence = Efficient Pathway to Market • Bioequivalence registration study in breast cancer patients (2014) - 12 months of duration (including patient recruitment) - Direct trial cost ~$5M Key Parameters*: 2 Abraxane® Cynviloq™ • Dose: 260 mg/m Cycle 1 (50 patients) (50 patients) • Infusion ti

  15. Slide 15: Cynviloq Advantages

    Slide 15: Cynviloq Advantages

    Cynviloq Advantages Cynviloq Cynviloq™ Abraxane® Taxol ® Advantage Maximum Tolerated Dose Potential for 2 >300 260 175 higher efficacy (mg/m ) Rapid reconstitution: Convenience for busy no foaming concerns practices and pharmacies No donor-derived human No viral / prion concerns serum albumin (HSA)

  16. Slide 16: Cynviloq Market Opportunity

    Slide 16: Cynviloq Market Opportunity

    Cynviloq Market Opportunity st ~70,000 patients treated with paclitaxel-based regimen in 1 line st 100,000 # of Patients Treated in 1 line (US Only; 2012) 90,000 ~55,000 patients with Other regimens paclitaxel as 1 st line therapy 80,000 PAC+ treated in MBC, NSCLC & OC 70,000 60,000 50,000 15,903 PC

  17. Slide 17: Potential to Expand Label Indications – 2nd Line Bladder Cancer

    Slide 17: Potential to Expand Label Indications – 2nd Line Bladder Cancer

    Potential to Expand Label Indications – nd For Example: 2 Line Bladder Cancer Cynviloq Best Supportive Care Phase 2 (Korea)* Phase 2 (Japan) **/ Phase 3 (EU)*** 260-300 mg/m² q3w n=23** / n=108*** n=34# Overall Response Rate (ORR) 21% - / 0%*** Progression Free Survival 2.7 M - / 1.5 M*** Overall Su

  18. Slide 18: Next Steps for Cynviloq

    Slide 18: Next Steps for Cynviloq

    Next Steps for Cynviloq 1. Bioequivalence (BE) trial: 2014 2. NDA filing: 2015 3. Approval: 2016 a. MBC and NSCLC b. Future Abraxane indications (Pancreatic cancer and Melanoma) 4. Product launch for MBC and NSCLC: 2016 5. sNDA planning for label expansion into Bladder and Ovarian cancers Bioequival

  19. Slide 19: RTX: Expanded Clinical Pipeline with Multiple Opportunities

    Slide 19: RTX: Expanded Clinical Pipeline with Multiple Opportunities

    Expanded Clinical Pipeline with Multiple Opportunities Intractable RTX Pain in Advanced Cancer 19

  20. Slide 20: Resiniferatoxin (RTX): Non-opiate Drug Candidate for Cancer Pain

    Slide 20: Resiniferatoxin (RTX): Non-opiate Drug Candidate for Cancer Pain

    Resiniferatoxin (RTX): Non-opiate Drug Candidate for Treating Cancer Pain “Prickly Painkiller: An experimental plant extract may end intractable pain with a single injection”* * Arlene Weintraub; Sci Am. 2013 Jul;309(1):14. 20

  21. Slide 21: RTX Ultra Potent and Selective Toxin

    Slide 21: RTX Ultra Potent and Selective Toxin

    RTX Ultra Potent and Selective Toxin Cross section of spinal cord after treatment* Pharmacology: RTX induces apoptosis of TRPV1- Ultra potent agonist of the TRPV1 receptor expressing afferent nerves. • < 2 pM TRPV1 receptor binding “ADC”-like killing, but no antibody-mediated Binding in primate ex-v

  22. Slide 22: Single Injection Addresses Cancer Pain in Dogs

    Slide 22: Single Injection Addresses Cancer Pain in Dogs

    Single Injection Addresses Cancer Pain in Dogs n=18 Single intrathecal injection Permanent ablation of nerves Attractive therapeutic effect (p < 0.0001 for all time points) All subjects responded Personality & mood of animals visibly improved n=18 n=8 n=5 n=4 No opioid-associated side effects Weeks

  23. Slide 23: Next Steps for Dual Pathway of RTX Development

    Slide 23: Next Steps for Dual Pathway of RTX Development

    Next Steps for Dual Pathway of RTX Development 2014 1. Intractable cancer pain clinical trial (intrathecal injection); n~40 patients 2. Phase 1/2 trial for intraganglionic injection (osteosarcoma); n~15 patients ~3 years for clinical development 23

  24. Slide 24: Pre-IND Immunotherapy Programs G-MAB ADC

    Slide 24: Pre-IND Immunotherapy Programs G-MAB ADC

    Pre-IND Immunotherapy Programs Antibodies G-MAB® + ADC Proprietary Toxins 24

  25. Slide 25: G-MAB: Library of Therapeutic Antibodies

    Slide 25: G-MAB: Library of Therapeutic Antibodies

    G-MAB®: Library of Therapeutic Antibodies • Proprietary technology • Very high library diversity: - RNA amplification used for 2.1 x 10 16 distinct antibodies library generation - Freedom-To-Operate • Fully human antibodies • No stacking royalties • High successful screening hit rate Most Difficult

  26. Slide 26: Anti-PD-L1 mAbs Exhibit Potent Activity

    Slide 26: Anti-PD-L1 mAbs Exhibit Potent Activity

    Anti-PD-L1 mAbs Exhibit Potent Activity Immune Modulation* Tumor Mouse Model** Day Competitor mAb Sorrento mAb * mAbs @ 0.05 mg/mL ** xenograft model using H1975 human NSCLC cells; % inhibition relative to control mAb treatment *** p<0.05, mean tumor volumes are significantly reduced in STI-A1010 gr

  27. Slide 27: Potent Antibody against Difficult GPCR Target

    Slide 27: Potent Antibody against Difficult GPCR Target

    Potent Antibody against Difficult GPCR Target* 3.5 Cell Binding mAb (EC50 – nM) Sorrento 0.17 3 Competitor 21 2.5 2 Untreated Sorrento mAb 1.5 1 0.5 0 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 Days After Disease Induction * Sorrento mAb against C-C Chemokine Recep

  28. Slide 28: Antibody Drug Conjugates (ADC)

    Slide 28: Antibody Drug Conjugates (ADC)

    Antibody Drug Conjugates (ADC) Key Components: 1. Target-specific internalizing antibody 2. Potent cytotoxic prodrugs 3. Linker and conjugation chemistries Drug released in CANCER CELL 28

  29. Slide 29: Proprietary ADC Screening and Optimization Panels

    Slide 29: Proprietary ADC Screening and Optimization Panels

    Proprietary ADC Screening and Optimization Panels • linkers • conjugation Payload pool Chemistry 20 panel 50 panel (up to) 20-panel for discovery of lead ADCs 3 benchmark ADCs for rapid POC studies 20 ADCs by rationale design with linker/conjugation technologies and payload pool 50-panel for generat

  30. Slide 30: K-lock Conjugation Enables Homogeneous ADCs

    Slide 30: K-lock Conjugation Enables Homogeneous ADCs

    K-lock Conjugation Enables Homogeneous ADCs Selective ADC chemistry Fewer positional isomers Better control of DAR 2 2 K-lock purified 1 3 0 30

  31. Slide 31: Irreversible C-lock-stabilized ADCs

    Slide 31: Irreversible C-lock-stabilized ADCs

    Irreversible C-lock-stabilized ADCs C-lock enhances ADC stability leading to: Prolonged PK profile Reduced off-target effects 31

  32. Slide 32: Proprietary Toxin Potency 30-fold Higher than DM1

    Slide 32: Proprietary Toxin Potency 30-fold Higher than DM1

    Proprietary Toxin Potency 30-fold Higher than DM1* SKBR3 (Breast Cancer Cell Line) IC50 (nM) Duo6 (K-lock) 0.017 Duo3 (K-lock) 0.019 DM1 (NHS) 0.3 (0.24 nM reported) MMAE (C-lock) 0.025 MMAE (maleimide) 0.035 cleavable MC-vc-PAB linker HCC1954 (Breast Cancer Cell Line) IC50 (nM) Duo6 (K-lock) 0.035

  33. Slide 33: G-MAB and ADC Pipeline

    Slide 33: G-MAB and ADC Pipeline

    G-MAB® and ADC Pipeline PD-L1 (STI-A100X) 1H 2015 PD-1 (STI-A110X) 1H 2015 Multiple VEGFR2-ADC (STI-A0168) 2H 2015 ONCOLOGY EGFR (STI-A020X) ADC Strategic c-Met (STI-A060X) ADC Her2 (STI-A160X) ADC Partnership CCR2 (STI-B020X) 2H 2015 ONCOLOGY / CCR2 (STI-B020X) ADC INFLAMMATION Opportunities (GPCR)

  34. Slide 34: Positioned to Become Oncology Leader

    Slide 34: Positioned to Become Oncology Leader

    Positioned to Become Oncology Leader Registration Cynviloq™ Trial Intractable Pain in RTX Advanced Cancer Antibodies G-MAB® + Proprietary ADC Toxins 34

  35. Slide 35: Oncology Drug, Antibody Library and ADC Company Valuations

    Slide 35: Oncology Drug, Antibody Library and ADC Company Valuations

    Small Molecule Oncology Drug, Antibody Library and ADC Company Valuations Company Small Molecule Antibody Targeted Mkt Cap* Oncology Drug Platform Drug Delivery Puma: PBYI MBC (Phase 3) ~$1.2B Pre-revenue Clovis: CLVS NSCLC, MBC (Phase 1) ~$1.6B Pre-revenue MorphoSys: MOR.DE Antibody ~$1.6B Pre-reve

  36. Slide 36: Investment Highlights

    Slide 36: Investment Highlights

    Investment Highlights Late Stage Oncology Drug with Exclusive US and EU Rights • Addresses multi-billion dollar paclitaxel market Abbreviated regulatory pathway (“bioequivalence”) for approval Cynviloq™ • • Bioequivalence registration trial in 2014 (study direct costs ~ $5M) • Product launch in 1H 2

  37. Slide 37: Sorrento Therapeutics

    Slide 37: Sorrento Therapeutics

    Sorrento Therapeutics Next-Generation Cancer Therapeutics Contact: Henry Ji President and CEO hji@sorrentotherapeutics.com (858) 668-6923

Source: SEC EDGAR · 8-K filed Nov 19, 2013

More decks from Sorrento Therapeutics, Inc.

All 41 Sorrento Therapeutics decks